Aims-To determine possible associations between p53 allelic deletion, c-Ki-ras mu 
USA). Cancer related death was taken as the end point for all survival analyses.
block were placed in a sterile 1 *5 ml Eppendorf tube with 700 VlI lysis buffer (50 mM Tris, pH 8-5, 1 mM EDTA, 0-5% Tween 20), boiled for 10 minutes, incubated for 48 hours at 37°C with proteinase K (0-4 mg/ml), and boiled to inactivate proteinase K. PCR products were generated on at least three separate occasions from all DNA templates to ensure that consistent results were obtained and to eliminate the possibility of inadvertent contamination from adjacent tumour/non-tumour material.
ALLELIC DELETION AT THE p53 TUMOUR SUPPRESSOR GENE LOCUS
The MspI restriction endonuclease identifies a biallelic RFLP in intron 6 of the p53 gene9 and the AccII restriction endonuclease identifies a biallelic RFLP within exon 4 of the p53 gene.'0 A novel 3' mismatch PCR was designed, exploiting the AccII site and the more cost-effective restriction endonuclease SmaI (fig 1) . The oligonucleotide primers used and reaction conditions for the PCR assay are outlined in table 1. Otherwise, assessment of allelic deletion was as described previously.9"0 DNA from 20 individuals was assayed to confirm that the SmaI genotype reflects accurately the AccII genotype (data not shown). PCR dilution experiments were also carried out to verify that preferential allele amplification did not occur.
c-Ki-ras MUTATIONAL ACTIVATION
The PCR assay used to detect the activating mutation at codon 12 of the c-Ki-ras oncogene was that of Haliassos et al.19 This technique is about 95% sensitive and can be expected to detect about 75% of all ras mutations in colorectal tumours. PCR products from non-
EXTRACTION OF DNA FROM PARAFFIN WAX EMBEDDED MATERIAL
Haematoxylin and eosin stained slides of paraffin wax embedded tissue were used in the selection of tumour material and non-tumour mucosa adjacent to colorectal tumours. Tumour material with more than 70% neoplastic cells was considered suitable for PCR based analysis and serial sections from the same blocks were used for immunohistochemical analysis. DNA was extracted from paraffin wax embedded tumour and non-tumour material using a boiling/proteinase K method. Briefly, three 20 gim sections from a representative Figure 3 shows nuclear and cytoplasmic immunostaining detected with CM1. Figure 4 shows wild-type and mutant c-Kiras alleles. Normal mucosa from 40 individuals examined was negative for the activating mutation. Wild-type c-Ki-ras was observed in mucosa 2 cm from the tumour margin (data not shown). Activating mutation at codon 12 was observed in 45 (40%) of 157 colorectal tumours. Figure 5 shows the sequence flanking codon 12 of the c-Ki-ras oncogene of two tumours, each exhibiting one wild-type allele and one mutant allele. p21ls immunostaining was detected in 78 (47%) of 167 colorectal carcinomas.
The data were tested for associations between ras and p53 aberrations and a number of clinicopathological variables (table 2) . Two significant associations were found; tumours which exhibited codon 12 c-Ki-ras mutation were smaller than those which did not (p= 0 049) and were more likely to be located in the rectum (p = 0 005). This latter finding was also observed for p21lras immunostaining (p= 0 024).
Survival analysis of the 168 patients with Dukes' stage B colorectal carcinoma revealed that none of the clinicopathological variables, either singly or in combination, was capable of predicting survival. Kaplan-Meier survival curves for p53 LOH, p53 immunostaining, cKi-ras mutational activation and p21ras immunostaining show that none of these parameters is predictive of survival ( fig 6) .
Discussion
One of the major difficulties complicating the management of Dukes' stage B colorectal car- 
